Mygest100 mg

Mygest is a natural progestin hormone used for the following indications:

Established / Approved Uses

• Secondary amenorrhea: Used to induce a withdrawal bleed in women with secondary amenorrhea due to inadequate endogenous progesterone production.
• Prevention of endometrial hyperplasia: Given cyclically with estrogen replacement therapy in non-hysterectomized postmenopausal women receiving estrogen, to oppose estrogen's stimulatory effect on the endometrium.

Guideline-Supported / Adjunct Uses

• Luteal phase support in assisted reproductive technology (ART): Used as part of combination protocols during in-vitro fertilization (IVF) and other ART cycles to support the endometrial lining and early pregnancy, typically alongside other fertility medications and under specialist supervision.
• Hormone replacement therapy (HRT): Used in combination with estrogen for relief of moderate-to-severe vasomotor (menopausal) symptoms in women with an intact uterus.

Vaginal and topical formulations of Mygest may have additional or different approved uses (e.g., threatened/recurrent miscarriage support in some countries); consult product-specific labeling and a physician.

Each oral capsule of Progesterone Micronized typically contains 100 mg or 200 mg of micronized natural progesterone suspended in peanut oil (or another oil carrier) inside a soft gelatin shell. Vaginal gel, insert, and injectable formulations of Progesterone Micronized are also available in some markets, with strength varying by product and route. Refer to the specific product packaging for exact strength and excipients.

Mygest is a bioidentical (structurally identical to endogenous human progesterone) hormone that has been physically processed ("micronized") into extremely fine particles. This micronization increases the surface area of the drug, improving its dissolution and oral bioavailability, since natural, non-micronized progesterone is poorly absorbed when taken by mouth. Mygest is used to replace or supplement the body's own progesterone in a variety of gynecologic and reproductive conditions, including secondary amenorrhea, luteal phase support during fertility treatment, and as the progestin component of menopausal hormone replacement therapy.

Progestin hormone (natural/bioidentical progesterone) — sex hormone used in gynecology and reproductive endocrinology. Mygest belongs to the class of natural progestins, distinct from synthetic progestins (progestogens) such as medroxyprogesterone acetate or norethisterone.

Pharmacodynamics

Progesterone Micronized binds to nuclear progesterone receptors in target tissues (endometrium, myometrium, breast, hypothalamus) and converts an estrogen-primed proliferative endometrium into a secretory endometrium. It also reduces myometrial excitability and contractility, and has mild diuretic, natriuretic, and CNS-depressant (sedative/anxiolytic) properties due to its neurosteroid metabolites.

Pharmacokinetics

Oral bioavailability of non-micronized progesterone is very low due to poor aqueous solubility and extensive first-pass hepatic metabolism; micronization increases the particle surface area and improves dissolution and absorption. Peak plasma concentrations of Progesterone Micronized are reached within 1-3 hours of oral dosing. It is highly protein-bound (to albumin and corticosteroid-binding globulin), extensively metabolized in the liver to various metabolites (including neuroactive metabolites responsible for drowsiness), and eliminated mainly via the kidneys as glucuronide/sulfate conjugates.

Mygest oral capsules should be swallowed whole with water, preferably at bedtime, because drowsiness and dizziness are common shortly after dosing. Follow product-specific food instructions, as taking it with food may alter absorption. Vaginal formulations of Mygest (gel, insert, or suppository) are inserted directly into the vagina per the product instructions and have different absorption characteristics than oral capsules — do not substitute one route for another without medical advice. Injectable formulations are administered intramuscularly by a healthcare professional. Missed doses should be taken as soon as remembered unless it is close to the next scheduled dose.

Mygest is metabolized primarily via hepatic CYP3A4. Clinically significant interactions include:

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir): may increase progesterone plasma levels, increasing sedation and other side effects.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort): may reduce progesterone levels and efficacy.
• CNS depressants (e.g., benzodiazepines, opioids, alcohol): additive sedation and dizziness when combined with Mygest.
• Estrogens: commonly co-administered by design in HRT regimens, but the combination carries a higher venous thromboembolism risk than either agent alone (see Precautions).

Inform your physician of all medications, supplements, and herbal products being used before starting Mygest.

Common side effects of Mygest include:

• Drowsiness, dizziness, or fatigue (especially within a few hours of oral dosing)
• Headache
• Breast tenderness or swelling
• Bloating, abdominal cramping
• Mood changes, irritability, or depression
• Nausea
• Vaginal spotting or irregular bleeding
• Joint pain

Less common but serious effects include venous thromboembolism (see Precautions), severe allergic reaction, and jaundice. Seek prompt medical attention for chest pain, shortness of breath, leg swelling/pain, sudden vision changes, or signs of an allergic reaction.

Mygest is used deliberately, under specialist supervision, for luteal phase support and early pregnancy maintenance in fertility treatment. For other indications, Mygest is contraindicated in known or suspected pregnancy. Outside of specialist-directed fertility care, Mygest should be used only if clearly needed, and only if the potential benefit justifies the potential risk to the fetus; consult a physician before use in pregnancy. Small amounts of progesterone pass into breast milk; caution is advised, and a physician should be consulted before using Mygest while breastfeeding.

Mygest commonly causes drowsiness and dizziness within a few hours of an oral dose; it is usually dosed at bedtime and patients should avoid driving or operating machinery until they know how the medicine affects them.

• Venous thromboembolism (VTE): Risk of blood clots (DVT, pulmonary embolism) is increased, particularly when Mygest is combined with estrogen therapy; discontinue immediately and seek medical care if signs of VTE occur.
• Mood and depression: Monitor for new or worsening depression, mood swings, or other psychiatric symptoms.
• Breast changes: Monitor for new lumps, pain, or discharge; report to a physician.
• Abnormal bleeding: Report any unexpected or irregular vaginal bleeding, which requires diagnostic evaluation.
• Peanut allergy: Many oral capsules of Mygest are formulated in peanut oil; avoid in patients with peanut allergy unless a peanut-oil-free formulation is confirmed.
• Route-specific considerations: Vaginal and injectable formulations of Mygest differ in absorption and dosing from oral capsules; do not interchange routes without medical guidance.

Overdose with Mygest may cause pronounced drowsiness, dizziness, confusion, or lethargy. There is no specific antidote. If an overdose of Mygest is suspected, seek immediate medical attention or contact a poison control center; supportive care and monitoring will be provided by medical professionals. Do not attempt to manage a suspected overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: Use with caution; clinical trials of Mygest in HRT did not include sufficient numbers of women over 65 to determine whether they respond differently, and increased sensitivity to CNS effects (drowsiness) may occur.

Hepatic impairment: Avoid use in significant hepatic impairment or active liver disease (see Contraindications).

Renal impairment: No well-established dose adjustment; use cautiously.

Peanut allergy: See Precautions — many oral formulations of Mygest contain peanut oil.

Pediatric population: Safety and efficacy of Mygest have not been established in children.

Duration of treatment with Mygest depends on the indication: a single 10-day course for inducing withdrawal bleeding in secondary amenorrhea (which may be repeated cyclically as directed); ongoing cyclic administration (e.g., 12 days per 28-day cycle) alongside estrogen for endometrial protection in HRT, continued for as long as HRT is used; and a defined course during the luteal phase and, if pregnancy occurs, into the early first trimester for ART support, as directed by the fertility specialist. Do not stop or extend treatment with Mygest without consulting the prescribing physician.

Progestin; natural (bioidentical) progesterone hormone; sex hormone.

Progesterone Micronized acts by binding to intracellular progesterone receptors, producing the physiological effects of endogenous progesterone: transformation of proliferative endometrium into secretory endometrium, reduction of uterine excitability, and, in combination with estrogen, prevention of estrogen-induced endometrial hyperplasia. It also has central nervous system effects (sedation) mediated through neuroactive metabolites acting on GABA-A receptors.

Category B (legacy FDA pregnancy category historically applied to oral micronized progesterone formulations)

Safety and efficacy of Mygest have not been established in pediatric patients. Mygest is not indicated for use in children, and use in adolescents should only occur under the direct supervision of a pediatric or adolescent gynecology specialist for specific, well-justified indications.